The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

119 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, randomized, double blind trial. The rationale of the study is the concept that fresh frozen plasma (FFP) is still largely used in cardiac surgery, despite the fact that prothrombin complexes and fibrinogen are available.The experimental hypothesis is that cardiac surgery patients may be operated with no use of FFP and with a coagulation factors replacement based on fibrinogen and prothrombin complexes (when needed).

Primary endpoint: Transfusion avoidance Secondary endpoints: Transfusion limitation, massive blood transfusion, bleeding.

Study population: high-risk adult cardiac surgery patients Sample size : 2 groups of 60 patients each

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients

NCT02750150

Trauma Coagulopathy

COMPLETED PHASE3

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

NCT05523297

Bleeding Cardiac Surgery Patients

COMPLETED PHASE3

ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery - Liver Bleeding is Encountered

NCT02264730

Bleeding

UNKNOWN PHASE1

Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures

NCT02637427

Blood Coagulation Disorders Hemorrhage

COMPLETED PHASE3

Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?

NCT00953901

Blood Coagulation, Disorders Surgical Procedures, Minimally Invasive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design Randomized, placebo-controlled, double-blinded study Endpoints Primary: Transfusion avoidance of every allogeneic blood product Secondary: Reduction in the number of allogeneic blood products used, reduction in massive blood transfusion events incidence, reduction in postoperative bleeding.

Patient population This study is focused on the role of coagulation factors substitutes in avoiding transfusions. Therefore, the patient population should be composed by patients being at high-risk for transfusions due to bleeding and not to hemodilution. Moreover, bleeding should be primarily due to a coagulation factors deficiency, rather than to other causes (namely, drug-induced platelet dysfunction).

The major determinant of coagulation factors consumption during cardiac operations is the length of CPB. Only patients undergoing operations with a predictable CPB duration \> 90 minutes will be admitted. This includes patients undergoing complex cardiac operations (double valve; CABG+valve; ascending aorta; adult congenital patients). Adult congenital patient may be of particular interest, since they usually have a preoperative reduced hepatic coagulation factors synthesis, due to venous stasis and polycythemia.

To avoid the effects of hemodilution in determining transfusional needs, patients with an expected lowest HCT \< 23% during CPB will not be admitted to the study. This means excluding patients with a preoperative HCT \< 35%, and patients with a small BSA (\< 1.7 m2). Hemodilution during CPB will be checked, and in case of a HCT value \< 23% the patient will be withdrawn from the study.

Power analysis and sample size

Data from our Institutional database (about 15,000 patients) have been retrieved according to the above reported selection criteria. 1,535 patients (10%) fulfill the randomization and no-withdrawal criteria.

Within this group, we could calculate the following outcome variables:

Variable Incidence Mean with SD Transfusion rate (any kind) 61% Packed red cells 57% FFP 31% Platelets 8% Big bleeders (\> 800 mL) 20% Postoperative bleeding 560±501 Surgical revision 5.7%

Based on these data, we could perform a power analysis based on an alpha value of 0.05 and a beta value of 0.20. According to these values, the required number of patients to be enrolled varies according to the experimental hypothesis:

Transfusion rate control group Hypothesis for transfusion rate in treatment group Number of patients per each group Total number of patients 60% 30% 40 80 60% 35% 58 116 60% 40% 94 188

The study size will be 116 patients (58 per group).

Study protocol

Patients in the control group will receive the standard treatment available in our Hospital for blood management and hemostasis and coagulation control. This includes antifibrinolytic administration (tranexamic acid 15 mg/kg before CPB and 15 mg/kg after protamine) Patients in both groups will be transfused according to our standard protocol (attachment 1)

Randomization: sealed envelopes. Enveloped placed in the pharmacy. Preparation of the drug vs. placebo by a dedicated biologist. Blinded vials sent to the OR.

Dosing protocol

All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a thromboelastometry fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.

After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.

In presence of ongoing microvascular bleeding intraoperatively or during the first 6 hours in the ICU, the patients will be treated with other drugs and products to control bleeding according to our standard protocol (see "Transfusion protocol").

After dosing, a blood sample will be withdrawn, centrifuge, and frozen plasma will be stored for subsequent Thrombin Generation Test.

Blinding:

An unblinded biologist will follow the drug randomization process, open the sealed envelope, drug preparation, and ROTEM analysis.

All the other Investigators will be blinded.

Transfusion protocol

1\. Definition of bleeding: Intraoperatively: delayed sterna closure due to microvascular bleeding Postoperatively: 2 mL/kg for 2 consecutive hours; or 1.5 ml/kg for 4 consecutive hours

Packed red cells will be transfused (one unit at a time) under the following conditions:

1. Always if Hb \< 7 g/dL
2. Possible if Hb between 7 and 8 g/dL
3. Possible but with medical justification (hemodynamic instability; high oxygen extraction rate; signs of organ ischemia…) if Hb between 8 and 9 g/dL
4. Never if Hb ≥ 9 g/dL

Fresh frozen plasma in case of bleeding if

1. INR \> 1.5
2. R time at TEG (with heparinase) \> 12 minutes

Platelets in case of bleeding if

1. Platelet count \< 50.000/mmc
2. Pre-treatment with thienopyridinies (not applicable in this study)

In case of intractable bleeding determining hemodynamic instability, and for all life-saving conditions, the above mentioned conditions may be not considered, and an empirical rescue therapy is allowed.

Funding This study will be funded internally with the IRCCS Policlinico San Donato Research Fund.

The drugs (fibrinogen concentrate and PCC) will be provided free of charge by CSL Behring, as well as the reagents for ROTEM analysis,

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline solution

Group Type PLACEBO_COMPARATOR

Saline solution

Intervention Type DRUG

Normal saline will be administered to control patients.

Fibrinogen

Group Type ACTIVE_COMPARATOR

Fibrinogen

Intervention Type DRUG

All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.

Prothrombin complex

Group Type ACTIVE_COMPARATOR

Prothrombin complex

Intervention Type DRUG

After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fibrinogen

All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.

Intervention Type DRUG

Saline solution

Normal saline will be administered to control patients.

Intervention Type DRUG

Prothrombin complex

After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RIASTAP Placebo CONFIDEX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patients will be screened according to a modified TRUST1 Transfusion Score. This score attributes 1 point to each of the following conditions:

* Hb level \< 13.5 g/dL
* Weight \< 77 kg
* Female sex
* Age \> 65 years
* Non elective surgery
* Serum creatinine \> 1.36 mg/dL
* Redo operation
* Non isolated surgery
* Factors are hemodilution-related factors, and will not be included. Non isolated surgery is mandatory for inclusion. Patients will be included in presence of at least 1 within the remaining 4 risk factors:
* Age \> 65 years
* Non elective surgery

1. Combined cardiac operation with expected CPB duration \> 90 minutes
2. At least one additional risk factor within the following: Age \> 65 years; Non elective surgery; Serum creatinine \> 1.36 mg/dL; Redo operation

Exclusion Criteria

1. Age \< 18 years
2. Patients under thienopyridines
3. Known coagulopathy
4. Known autoimmune disorders
5. Participation in another RCT
6. Pregnancy
7. Emergency operation
8. Baseline HCT \< 35%
9. Baseline Antithrombin \< 80%
10. BSA \< 1.7 m2

WITHDRAWAL CRITERION:

1. Lowest HCT on CPB \< 23%
2. Transfusions during CPB

* Patients randomized and not withdrawn will be DOSED with the investigational drugs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No